Usage of plerixafor has shown dramatic reduction in carcinogenic phenotype induced by CXCR4 in various in vitro cancer studies in solid tumours such as prostate and cervical cancers (Chaudary et al., 2017; Conley‐LaComb et al., 2016), as well as lymphomas (Reinholdt et al., 2016). Here, CXCR4 is linked to cervical cancer.